Systemic Lupus Erythematosus and COVID-19.
Maria PappaAlexandros PanagiotopoulosKonstantinos ThomasAntonis FanouriakisPublished in: Current rheumatology reports (2023)
Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications.
Keyphrases
- systemic lupus erythematosus
- sars cov
- coronavirus disease
- disease activity
- mechanical ventilation
- respiratory syndrome coronavirus
- end stage renal disease
- acute respiratory distress syndrome
- intensive care unit
- ejection fraction
- newly diagnosed
- chronic kidney disease
- immune response
- prognostic factors
- peritoneal dialysis
- skeletal muscle
- respiratory failure
- patient reported outcomes
- metabolic syndrome
- patient reported
- extracorporeal membrane oxygenation
- climate change
- hodgkin lymphoma